FDA approves weight loss drug Zepbound for sleep apnea - NBC News
2 days ago · The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in adults with obesity, the drugmaker Eli Lilly said Friday.The decision makes ...
Zepbound sheds more weight than Wegovy in trial, Eli Lilly says - NBC News
Dec 4, 2024 · People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a head-to-head clinical trial, Lilly said in a news release Wednesday.
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Dec 4, 2024 · While both medications showed a significant weight loss benefit, after 72 weeks on treatment, people treated with Zepbound lost 20% of their body weight, compared to people on Wegovy who lost just under 14%. This translates to people on Zepbound losing roughly 50 pounds compared to 33 pounds on Wegovy during the 72-week trial.
Zepbound leads to more weight loss than Wegovy, drugmaker …
Dec 4, 2024 · Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.
Weight loss: Zepbound More Effective than Wegovy, Eli Lilly Says
Dec 5, 2024 · Zepbound led to more long-term weight loss than Wegovy in a new clinical trial from drugmaker Eli Lilly. Lilly officials said 31% of people taking Zepbound lost at least 25% of their body...
FDA approves weight-loss drug Zepbound for obstructive sleep …
2 days ago · Participants on Zepbound also lost significant amounts of weight: about 18% of their body weight, on average, in the first trial and about 20% in the second, compared with 1.6% and 2.3% ...
F.D.A. Approves Weight-Loss Drug to Treat Sleep Apnea
2 days ago · The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the common sleep disorder.
Zepbound outperforms Ozempic and Wegovy in head-to-head weight loss …
Jul 8, 2024 · Tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, leads to more weight loss than semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, new research...
Eli Lilly's Zepbound tops Wegovy in head-to-head weight loss trial
Dec 4, 2024 · Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly...
Zepbound tops Wegovy for weight loss in Eli Lilly study
Dec 4, 2024 · Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk. Lilly said patients taking Zepbound lost about 20% of their weight on average compared to nearly 14% for Wegovy.